Unknown

Dataset Information

0

CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines.


ABSTRACT: In 90% of pancreatic ductal adenocarcinoma cases, genetic alteration of the proto-oncogene Kras has occurred, leading to uncontrolled proliferation of cancerous cells. Targeting Kras has proven to be difficult and the battle against pancreatic cancer is ongoing. A promising approach to combat cancer was the discovery of the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas) system, which can be used to genetically modify cells. To assess the potential of a CRISPR/CRISPR-associated protein 9 (Cas9) method to eliminate Kras mutations in cells, we aimed to knock-out the c.35G>A (p.G12D) Kras mutation. Therefore, three cell lines with a heterozygous Kras mutation (the human cell lines SUIT-2 and Panc-1 and the cell line TB32047 from a KPC mouse model) were used. After transfection, puromycin selection and single-cell cloning, proteins from two negative controls and five to seven clones were isolated to verify the knock-out and to analyze changes in key signal transduction proteins. Western blots showed a specific knock-out in the KrasG12D protein, but wildtype Kras was expressed by all of the cells. Signal transduction analysis (for Erk, Akt, Stat3, AMPK?, and c-myc) revealed expression levels similar to the wildtype. The results described herein indicate that knocking-out the KrasG12D mutation by CRISPR/Cas9 is possible. Additionally, under regular growth conditions, the knock-out clones resembled wildtype cells.

SUBMITTER: Lentsch E 

PROVIDER: S-EPMC6888344 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

CRISPR/Cas9-Mediated Knock-Out of Kras<sup>G12D</sup> Mutated Pancreatic Cancer Cell Lines.

Lentsch Eva E   Li Lifei L   Pfeffer Susanne S   Ekici Arif B AB   Taher Leila L   Pilarsky Christian C   Grützmann Robert R  

International journal of molecular sciences 20191114 22


In 90% of pancreatic ductal adenocarcinoma cases, genetic alteration of the proto-oncogene Kras has occurred, leading to uncontrolled proliferation of cancerous cells. Targeting Kras has proven to be difficult and the battle against pancreatic cancer is ongoing. A promising approach to combat cancer was the discovery of the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas) system, which can be used to genetically modify cells. To assess the potential of a  ...[more]

Similar Datasets

| S-EPMC7749119 | biostudies-literature
| S-EPMC8321670 | biostudies-literature
| S-EPMC6523736 | biostudies-literature
| S-EPMC5634636 | biostudies-literature
| S-EPMC7794028 | biostudies-literature
| S-EPMC6722079 | biostudies-literature
| S-EPMC5762654 | biostudies-literature
| S-EPMC10085040 | biostudies-literature
| S-EPMC8800938 | biostudies-literature
| S-EPMC5639827 | biostudies-other